Researcher Unveils New Approach to Blocking Malaria Transmission

	Tweet

University of Illinois at Chicago researcher Dr. John Quigley will describe a promising new approach to blocking malaria transmission during the American Society of Hematology’s annual meeting in Orlando, Fla.

Quigley will speak at a press briefing Saturday, Dec. 4, at 8 a.m. at the Orange County Convention Center, 9800 International Drive, Room 208C (West Building). His abstract, “Anopheline Orthologs of the Human Erythroid Heme Exporter, FLVCR, Export Heme: Potential Targets to Inhibit Plasmodium Transmission,” will be presented at the plenary session Sunday.

The research focuses on potential targets to inhibit transmission of the parasite Plasmodium that causes malaria.

Female mosquitoes ingest large amounts of hemoglobin that serves as a food source required for mosquito egg development. When a mosquito ingests infected blood, Plasmodium reproduces in the mosquito gut. Plasmodium fertilized egg cells cross the lining of the mosquito gut and develop into oocysts. After maturing, the oocysts rupture and release thousands of parasites that allow the mosquito to transmit malaria when it bites another human.

Previous studies have shown that mosquitoes with increased oxidative stress in their midgut are resistant to Plasmodium transmission. Quigley and his colleagues hypothesize that if they can disrupt the function of a cell-surface transport protein called FLVCR that pumps heme out of the cell, it will increase the oxidative stress in the mosquito gut and hamper Plasmodium at a crucial point in the parasite’s life cycle.

The researchers isolated the FLVCR gene from two common malaria-transmitting mosquitoes and showed that the gene encodes a protein that exports heme and protects cells from oxidative stress. Using gene-silencing techniques, they were able to significantly reduce levels of FLVCR in the mosquito gut.

“If disruption of the function of the protein inhibits parasite transmission, then we can potentially use parts of the protein as an antigen to try to stimulate a vaccine in people,” said Quigley, who is assistant professor of medicine at the UIC College of Medicine and senior author of the study. “So the antibody blocks FLVCR and increases oxidative stress, and now the Plasmodium is not able to complete its life cycle, thus preventing the spread of malaria.”

Quigley’s research is ongoing, and future studies will focus on whether inhibiting FLVCR can block Plasmodium transmission. The research, he says, may be applicable to all blood-eating insects that cause a variety of diseases, such as West Nile Virus, dengue fever and leishmaniasis.

Quigley is a member of the UIC Cancer Center.

UIC ranks among the nation’s leading research universities and is Chicago’s largest university with 27,000 students, 12,000 faculty and staff, 15 colleges and the state’s major public medical center. A hallmark of the campus is the Great Cities Commitment, through which UIC faculty, students and staff engage with community, corporate, foundation and government partners in hundreds of programs to improve the quality of life in metropolitan areas around the world.

###

Source:  University of Illinois at Chicago

RELATED STORIES:
Cancer center will offer state-of-the-art services   African American men say doctor visits are often a bad experience   Personalized Web messages help smokers quit   House takes another step on healthcare reform   Mexico breathes easier but flu pandemic likely   Mass vaccinations to fight yellow fever in Africa   Some free medicine programs too complex: survey   Smoking-related deaths to rise sharply in India   Schiavo case sparks sympathy, scorn among Dutch   A good wife, a good grip, a good education and no ciggies and you’ll live to 85!!   Gene test users largely satisfied, survey finds   New study shows rise in drug resistance of dangerous infection in US hospitals

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]